IL114179A - Interleukin-5 specific recombinant antibodies - Google Patents

Interleukin-5 specific recombinant antibodies

Info

Publication number
IL114179A
IL114179A IL11417995A IL11417995A IL114179A IL 114179 A IL114179 A IL 114179A IL 11417995 A IL11417995 A IL 11417995A IL 11417995 A IL11417995 A IL 11417995A IL 114179 A IL114179 A IL 114179A
Authority
IL
Israel
Prior art keywords
interleukin
recombinant antibodies
specific recombinant
specific
heavy
Prior art date
Application number
IL11417995A
Other languages
English (en)
Other versions
IL114179A0 (en
Original Assignee
Celltech Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Therapeutics Ltd filed Critical Celltech Therapeutics Ltd
Publication of IL114179A0 publication Critical patent/IL114179A0/xx
Publication of IL114179A publication Critical patent/IL114179A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL11417995A 1994-06-17 1995-06-15 Interleukin-5 specific recombinant antibodies IL114179A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9412230A GB9412230D0 (en) 1994-06-17 1994-06-17 Interleukin-5 specific recombiant antibodies

Publications (2)

Publication Number Publication Date
IL114179A0 IL114179A0 (en) 1995-10-31
IL114179A true IL114179A (en) 2001-08-26

Family

ID=10756925

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11417995A IL114179A (en) 1994-06-17 1995-06-15 Interleukin-5 specific recombinant antibodies

Country Status (18)

Country Link
US (3) US5998586A (xx)
EP (1) EP0765392B1 (xx)
JP (1) JP3973682B2 (xx)
AT (1) ATE264389T1 (xx)
AU (1) AU694783B2 (xx)
CA (1) CA2192543C (xx)
CZ (1) CZ292295B6 (xx)
DE (1) DE69532889T2 (xx)
ES (1) ES2218546T3 (xx)
FI (1) FI965032A0 (xx)
GB (1) GB9412230D0 (xx)
HU (1) HU221641B1 (xx)
IL (1) IL114179A (xx)
NO (1) NO964808L (xx)
NZ (1) NZ287927A (xx)
SK (1) SK282625B6 (xx)
WO (1) WO1995035375A1 (xx)
ZA (1) ZA954990B (xx)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39548E1 (en) 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
CZ297045B6 (cs) * 1994-12-23 2006-08-16 Smithkline Beecham Corporation Hlodavcí neutralizacní monoklonální protilátka, zpusob pro její produkci, kompozice s jejím obsahema pouzití, hybridom a jím produkovaná protilátka,fab fragment, komplementaritu urcující region, molekula nukleové kyseliny a její sekvence, plasmid a
EE200100552A (et) * 1999-04-23 2002-12-16 Pharmexa A/S Meetod kasvuteguri IL-5 aktiivsuse in vivo mahasurumiseks, IL-5 analoog, seda kodeeriv nukleiinhappefragment ning kasutamine immunogeense kompositsiooni valmistamiseks
EP2027157B1 (en) 2006-05-25 2014-08-06 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
EP2274009B1 (en) 2008-03-28 2013-11-13 GlaxoSmithKline LLC Methods of treatment
CN102239182B (zh) * 2008-10-06 2014-07-09 米纳瓦生物技术公司 Muc1*抗体
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3431485B1 (en) 2010-10-01 2020-12-30 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
CN103429261A (zh) * 2010-12-22 2013-12-04 塞法隆澳大利亚股份有限公司 半寿期改进的修饰抗体
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AU2012318752B2 (en) 2011-10-03 2017-08-31 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2833923A4 (en) 2012-04-02 2016-02-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
JP6502856B2 (ja) 2012-12-26 2019-04-17 オンコシナジー インコーポレイテッド 抗インテグリンβ１抗体組成物及びその使用方法
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
WO2016004045A1 (en) * 2014-06-30 2016-01-07 Academia Sinica Antagonists for interleukin-17 receptor b (il-17rb) and its ligand il-17b for cancer therapy
CA2976089A1 (en) 2015-02-10 2016-08-18 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
KR20180037275A (ko) 2015-08-24 2018-04-11 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 생물제약 조성물
US11390671B2 (en) 2017-06-06 2022-07-19 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients
AU2018340557A1 (en) 2017-09-29 2020-04-09 Jiangsu Hengrui Medicine Co., Ltd. IL-5 antibody, antigen binding fragment thereof, and medical application therefor
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
CN111303284A (zh) * 2018-12-12 2020-06-19 尚华科创投资管理（江苏）有限公司 抗人白细胞介素5(il-5)单克隆抗体及其应用
MX2021011530A (es) 2019-03-29 2021-10-22 Jiangsu Hengrui Medicine Co Composicion farmaceutica que contiene anticuerpos contra il-5 y su uso.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0441891A1 (en) * 1988-11-03 1991-08-21 Schering Corporation Method of preventing or reducing eosinophilia
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU8910891A (en) * 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
RU94045919A (ru) * 1992-02-06 1996-11-10 Шеринг Корпорейшн (US) Антитела, клетки, полипептид, днк векторы, способ получения полипептида, способ получения антитела, фармацевтическая композиция
DE69321218T2 (de) * 1992-02-19 1999-02-18 Schering Corp Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies

Also Published As

Publication number Publication date
US5998586A (en) 1999-12-07
WO1995035375A1 (en) 1995-12-28
HU221641B1 (hu) 2002-12-28
HUT76672A (en) 1997-10-28
FI965032A (fi) 1996-12-16
ATE264389T1 (de) 2004-04-15
CA2192543A1 (en) 1995-12-28
NO964808L (no) 1997-02-17
ES2218546T3 (es) 2004-11-16
SK282625B6 (sk) 2002-10-08
EP0765392A1 (en) 1997-04-02
DE69532889T2 (de) 2005-03-10
JP3973682B2 (ja) 2007-09-12
CZ292295B6 (cs) 2003-08-13
US20020042089A1 (en) 2002-04-11
IL114179A0 (en) 1995-10-31
CZ371296A3 (cs) 1998-05-13
HU9603183D0 (en) 1997-01-28
FI965032A0 (fi) 1996-12-16
DE69532889D1 (de) 2004-05-19
CA2192543C (en) 2008-07-29
US6316227B1 (en) 2001-11-13
ZA954990B (en) 1996-12-17
AU694783B2 (en) 1998-07-30
NO964808D0 (no) 1996-11-13
SK160096A3 (en) 1997-06-04
AU2680395A (en) 1996-01-15
EP0765392B1 (en) 2004-04-14
NZ287927A (en) 1998-07-28
US6734286B2 (en) 2004-05-11
GB9412230D0 (en) 1994-08-10
JPH10501697A (ja) 1998-02-17

Similar Documents

Publication Publication Date Title
HU9603183D0 (en) Interleukin-5 specific recombinant antibodies
NO955167L (no) Monoklonalt anti-V-integrin-antistoff
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
AU8432498A (en) Human-cd28 specific monoclonal antibodies for antigen non-specific activation oft-lymphocytes
EP0870826A4 (en) NEW PROTEINS AND MONOCLONAL ANTIBODIES AGAINST THESE
AU628948B2 (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
HUP9904620A3 (en) Purified sperm surface antigen,monoclonal antibody therefor and applications therefor
EP0578515A3 (en) Humanized monoclonal antibodies.
AU6702998A (en) Anti-alphabeta3 humanized monoclonal antibodies
AU6031090A (en) Monoclonal antibodies against a tumor-associated antigen
BR9509902A (pt) Fragmentos de anticorpos monoclonais apresentando atividade imunosupressante
EP0554458A4 (en) Immunoassay, monoclonal antibody and hybridoma
EP0654532A4 (en) ANTIMUCOGLYCOPROTEIN MONOCLONAL ANTIBODIES.
AU5449390A (en) Monoclonal antibody against c-reactive protein
NO985281D0 (no) Monoklonalt antihumant MP52-antistoff
AU2002300457A1 (en) Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies
EP0668923A4 (en) MONOCLONAL ANTIBODY.
FI960566A (fi) Monoklonaalinen vasta-aine, joka tunnistaa välisolun pinta-antigeenin
BR1100555B1 (pt) anticorpos monoclonais humanizados.
IE901956L (en) Monoclonal antibody.
AU8547291A (en) Monoclonal antibodies against tenascin
GB9212074D0 (en) Monoclonal antibody
AU4283793A (en) Monocyte adhesion protein and monoclonal antibody thereto

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired